Atara Biotherapeutics, Inc.
ATRA
$7.32
-$0.28-3.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1,404.02% | 2,111.34% | 809.03% | -39.63% | -86.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,404.02% | 2,111.34% | 809.03% | -39.63% | -86.51% |
| Cost of Revenue | -26.01% | -25.12% | -25.12% | -18.50% | -15.53% |
| Gross Profit | 81.87% | 66.18% | 48.52% | 12.43% | -6.33% |
| SG&A Expenses | -22.63% | -19.82% | -26.13% | -25.51% | -26.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.40% | -24.22% | -25.31% | -19.85% | -17.83% |
| Operating Income | 70.91% | 58.19% | 44.35% | 15.50% | 1.92% |
| Income Before Tax | 69.06% | 54.13% | 40.55% | -8.45% | -20.95% |
| Income Tax Expenses | -180.00% | 200.00% | -54.29% | -50.00% | 25.00% |
| Earnings from Continuing Operations | 69.07% | 54.12% | 40.55% | -8.44% | -20.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.07% | 54.12% | 40.55% | -8.44% | -20.95% |
| EBIT | 70.91% | 58.19% | 44.35% | 15.50% | 1.92% |
| EBITDA | 72.29% | 59.30% | 45.14% | 15.71% | 1.65% |
| EPS Basic | 80.28% | 63.01% | 46.76% | -1.74% | -16.72% |
| Normalized Basic EPS | 81.22% | 65.83% | 49.08% | 19.68% | 4.67% |
| EPS Diluted | 80.28% | 63.01% | 46.76% | -1.66% | -16.63% |
| Normalized Diluted EPS | 81.22% | 65.83% | 49.08% | 19.65% | 4.64% |
| Average Basic Shares Outstanding | 76.59% | 40.68% | 22.68% | 11.93% | 3.84% |
| Average Diluted Shares Outstanding | 76.59% | 40.68% | 22.68% | 11.86% | 3.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |